Throughout this series, we've talked about the growth of the direct access testing industry and the types of models developed to support the businesses that are using that type of testing.
We've covered reimbursement considerations and physician ordering and specimen collection regulations. How does all of this come together to shape the future of the lab testing industry?
On the final episode of our four-part series on direct access laboratory testing, Epstein Becker Green attorneys Bob Hearn, James Boiani, and Megan Robertson discuss licensing and operational considerations, as well as where the lab testing industry is headed.
About the Diagnosing Health Care Podcast
What health care and life sciences decision-makers need to lead, comply, and compete. The health care industry is full of high-stakes legal, policy, and regulatory obstacles. And significant opportunities for those prepared to act on them. Diagnosing Health Care® delivers the intelligence executives, general counsel, and administrators need to navigate both. Part of the Epstein Becker Green Insights Network.
Email Notifications
Follow Us
Never miss an episode! Subscribe to Diagnosing Health Care on your preferred platform:
Also on Audible | Deezer | Goodpods | iHeartRadio | PlayerFM | Pocket Casts | YouTube Music
People
- Member of the Firm
- Member of the Firm
- Member of the Firm
Services
- Academic and Clinical Research
- Corporate Compliance Program Development, Implementation, and Effectiveness
- Drug and Medical Device Distribution
- FDA Inspections and Enforcement
- Health Care
- Health Care and Life Sciences Investigations and Enforcement
- Health Care and Life Sciences Investor Services
- Industry Research and Clinical Trials
- Life Sciences
- Life Sciences Due Diligence
- Product Marketing and Compliance
- Regulatory Strategy, Product Development, and Product Approvals
- Telehealth